← All trials
NCT03048825
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2017
- Primary completion
- Jun 30, 2021
- Completion date
- Dec 30, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 4000
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- McMaster UniversityLead sponsor
- McMaster UniversityOverall official - principal investigator
- Boston Scientific CorporationCollaborator
- Canadian Institutes of Health Research (CIHR)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.